Retatrutide Clinical Trials: The TRIUMPH Programme and How to Enrol
Quick answer: Retatrutide clinical trials run under two programmes — TRIUMPH for obesity indications and TRANSCEND-T2D for diabetes — comprising roughly eight pivotal trials plus a separate cardiovascular outcomes study. Most have completed enrolment and reported. Enrolment is the only legitimate way to receive retatrutide, it is always free, and no intermediary can sell you access. Trials are searchable on ClinicalTrials.gov by location.
The TRIUMPH Programme
TRIUMPH is Eli Lilly’s Phase 3 programme for retatrutide in weight management. Together with the separate TRANSCEND-T2D diabetes programme, it enrolled more than 5,800 participants, alongside a cardiovascular outcomes trial of roughly 10,000.
| Trial | Population | Status |
|---|---|---|
| TRIUMPH-1 | Obesity or overweight, no diabetes (n=2,339) | Reported May 2026 |
| TRIUMPH-2 | Obesity with type 2 diabetes | Reported July 2026 |
| TRIUMPH-3 | Severe obesity + cardiovascular disease (n=1,949) | Reported July 2026 |
| TRIUMPH-4 | Obesity + knee osteoarthritis | Reported December 2025 |
| TRIUMPH-5 | Head-to-head vs tirzepatide (n≈800) | Active, not recruiting |
| TRIUMPH-Outcomes | Cardiovascular outcomes (n≈10,000) | Ongoing |
| TRANSCEND-T2D-1 | Type 2 diabetes (n=537) | Reported March 2026 |
| TRANSCEND-T2D-2 and -3 | Type 2 diabetes, further arms | Ongoing |
An obstructive sleep apnoea substudy was nested within TRIUMPH-1 rather than run as a standalone trial. For what each of these produced, see the full results from each trial.
Which Trials Are Still Enrolling
This is the practical question, and the answer has narrowed considerably during 2026.
The four core TRIUMPH obesity trials have completed enrolment and reported. TRIUMPH-5 is listed as active but not recruiting — its 800 places are filled and it completes in December 2026. TRIUMPH-Outcomes and the remaining TRANSCEND-T2D arms are the trials most likely to have open sites, though availability varies by location and changes constantly.
Because status shifts week to week, a static list on any website goes stale quickly. ClinicalTrials.gov is the authoritative source and it updates as sites open and close. For where the regulatory filing stands alongside the trial programme, see current filing and approval status.
How to Find a Retatrutide Trial Near You
- Go to ClinicalTrials.gov
- Search retatrutide or the development code LY3437943 — searching both catches listings indexed under either name
- Filter recruitment status to Recruiting or Not yet recruiting
- Enter your city or postcode and set a distance radius
- Open a study record and read the eligibility criteria before contacting anyone
- Use the contact details in the study record to reach the site coordinator directly
Outside the US, the ISRCTN registry and the EU Clinical Trials Register list studies running in those regions — UK trial registries and MHRA status covers the British picture in more detail.
One thing to know before you start: enrolment is always free, and no legitimate service sells access to a trial. Any site charging a fee to secure a place, guarantee admission, or supply “clinical trial grade” retatrutide is not connected to the programme. Screening runs through the trial site itself, and the site contacts you. Why trial enrolment is the only legitimate route sets out what the alternatives actually are.
Who Qualifies
Criteria vary by trial, but the obesity arms have shared broad requirements.
Typically eligible: adults with a BMI of 30 or above, or 27 and above with a weight-related condition such as hypertension, dyslipidaemia, sleep apnoea, or cardiovascular disease. Diabetes-specific trials require a diagnosis of type 2 diabetes with HbA1c in a defined range.
Common exclusions: recent use of other weight-loss medication, prior bariatric surgery, type 1 diabetes, a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, pregnancy or planned pregnancy, and significant recent cardiovascular events.
Screening involves blood work, physical assessment, and medical history review. Being screened does not guarantee enrolment — a meaningful proportion of volunteers are excluded at this stage.
What Participation Involves
- Randomisation. Most trials include a placebo arm, so enrolling does not guarantee you receive retatrutide. TRIUMPH-5 is an exception — it compares retatrutide against tirzepatide, so every participant receives an active drug. See what TRIUMPH-5 is designed to settle.
- Duration. Trials in this programme have run 40 to 104 weeks.
- Visits. Frequent early on, typically every four weeks during dose escalation, then spacing out.
- Monitoring. Regular blood work, weight and vital signs, and adverse event reporting — the adverse event data from these trials shows what has been recorded so far.
- Cost. No charge to participants. Sites commonly reimburse travel and may offer compensation for time.
- Withdrawal. You can leave at any point, for any reason, without giving one.
Is There a Retatrutide Parkinson’s Trial?
No. Retatrutide has not been studied in Parkinson’s disease, and no such trial is registered.
The question comes up because GLP-1 drugs genuinely have been investigated for Parkinson’s — just not this one. The compounds tested are exenatide, lixisenatide, and NLY01:
- Exenatide — a Phase 3 UK trial published in The Lancet in February 2025 found no effect on disease progression, effectively closing that line of inquiry for exenatide
- Lixisenatide — a Phase 2 trial published in the New England Journal of Medicine in 2024 found motor scores held steady against decline in the placebo group, a small but statistically significant difference
- NLY01 — a pegylated exenatide analogue, showed no benefit in early Parkinson’s in Phase 2
Retatrutide’s Phase 3 programme covers obesity, type 2 diabetes, knee osteoarthritis, sleep apnoea, and cardiovascular outcomes. Neurodegenerative disease is not among its studied indications.
For trial results, safety data, dosing schedules, cost, and comparisons with approved alternatives, browse all retatrutide research and analysis.
Frequently Asked Questions
Are retatrutide clinical trials still recruiting?
The four core TRIUMPH obesity trials have completed enrolment. TRIUMPH-5 is active but not recruiting. TRIUMPH-Outcomes and remaining TRANSCEND-T2D arms are most likely to have open sites. Check ClinicalTrials.gov for current status, which changes weekly.
How do I find a retatrutide trial near me?
Search ClinicalTrials.gov for retatrutide or LY3437943, filter to Recruiting, and enter your location with a distance radius. Contact the site coordinator listed in the study record directly.
Does it cost anything to join a trial?
No. Participation is free and sites often reimburse travel. No legitimate intermediary sells access to a clinical trial.
Will I definitely receive retatrutide if I enrol?
Not necessarily. Most trials include a placebo arm. TRIUMPH-5 is the exception, comparing retatrutide against tirzepatide, so all participants receive an active drug.
Is there a retatrutide Parkinson’s disease trial?
No. Retatrutide has not been studied in Parkinson’s. GLP-1 research in Parkinson’s has involved exenatide, lixisenatide, and NLY01 — not retatrutide.
What were the retatrutide clinical trial results?
TRIUMPH-1 produced 28.3% weight loss at 80 weeks, TRIUMPH-4 28.7% at 68 weeks, TRIUMPH-3 22.6% at 80 weeks in a cardiovascular disease population, and TRANSCEND-T2D-1 reduced HbA1c by up to 1.94 points.
Can I join a trial outside the US?
Yes, where sites exist. The ISRCTN registry and EU Clinical Trials Register list studies in those regions, and ClinicalTrials.gov includes many international sites.
Sources
- Giblin K, Kaplan LM, Somers VK, et al. “Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.” Diabetes Obes Metab. 2026;28(1):83–93.
- Eli Lilly. TRIUMPH-1 topline, May 2026; TRIUMPH-2 and TRIUMPH-3 topline, 23 July 2026; TRIUMPH-4 topline, December 2025.
- Vijiaratnam N, et al. “Exenatide once a week versus placebo in Parkinson’s disease: a phase 3 trial.” The Lancet. 2025.
- “Trial of Lixisenatide in Early Parkinson’s Disease.” N Engl J Med. 2024.
- ClinicalTrials.gov: TRIUMPH-1 (NCT05929066), TRIUMPH-5 (NCT06662383), TRANSCEND-T2D-1 (NCT06354660).